Key result
Direct thrombin inhibitors like melagatran inhibit both fibrin formation and platelet activation ex vivo.
Why the study?
Do direct thrombin inhibitors (DTIs) improve the inhibition of fibrin formation and platelet activation compared to low-molecular-weight heparins (LMWHs) in an ex vivo human thrombosis model?
Do direct thrombin inhibitors (DTIs) improve the inhibition of fibrin formation and platelet activation compared to low-molecular-weight heparins (LMWHs) in an ex vivo human thrombosis model?
Direct thrombin inhibitors, particularly melagatran, inhibit both fibrin formation and platelet activation in an ex vivo human thrombosis model, suggesting potential clinical advantages over LMWHs.
Hypothesis-generating for DTI advantages over LMWHs in thrombosis; clinical trials needed before any practice implications.
Direct thrombin inhibitors (DTIs) such as hirudins and melagatran are currently developed for antithrombotic therapy. They should possess some advantages over the currently used low-molecular-weight heparins (LMWHs). They may also act through an inhibition of thrombin-induced platelet activation. The antithrombotic effects of DTIs and of LMWHs were investigated in an ex vivo thrombosis model with human blood in order to analyze the inhibition of thrombin-antithrombin as well as the platelet factor 4 formation. The data show that DTIs inhibit both fibrin formation and platelet activation, which is of clinical relevance especially for melagatran.
No takes yet. Share an insight, caveat, or question.
Harenberg et al. (2002) studied Thrombosis. Direct thrombin inhibitors (DTIs) vs. Low-molecular-weight heparins (LMWHs) was evaluated on Inhibition of thrombin-antithrombin and platelet factor 4 formation. Direct thrombin inhibitors, especially melagatran, inhibit both fibrin formation and platelet activation in an ex vivo human thrombosis model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: